SCHEMBL2169997

SCHEMBL2169997

Cc1ccccc1S(=O)(=O)N1N(C2C3CC4CC(C3)CC2C4)C(=O)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSG P08311 1/20 0.40
CMA1 P23946 1/20 0.40
EPHX2 P34913 2/20 0.37
CCR1 P32246 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.34
PAX8 Q06710 1/20 0.34
NR3C1 P04150 1/20 0.33
HSD11B1 P28845 1/20 0.33
HDAC1 Q13547 2/20 0.32
FNTA P49354 1/20 0.32
PGGT1B P53609 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168942 0.88 NPSR1 (0.42) EPHX2NR3C1HSD11B1HTR2AHTR2C
SCHEMBL2170001 0.88 FAAH (0.40) CTSGCMA1CCR1HSD11B1
SCHEMBL2170125 0.85 SMN1; SMN2 (0.37) HSD11B1CYP2C9TSHRALDH1A1POLB
SCHEMBL2169948 0.78 KMT2A (0.44) HSD11B1TSHRALDH1A1LMNAPOLB
SCHEMBL2170303 0.76 MEN1 (0.44) CTSGCMA1HSD11B1HTR2AHTR2C
SCHEMBL2168805 0.75 EPHX2 (0.38) EPHX2CNR2HSD11B1
SCHEMBL2170813 0.72 PTGS1 (0.38) HSD11B1TSHRALDH1A1LMNAPOLB
SCHEMBL2169693 0.72 ITGB1 (0.42) CYP3A4CYP2C9CYP2C19ALDH1A1POLB
SCHEMBL2169423 0.71 MAPK1 (0.32) CNR2NR3C1HSD11B1
SCHEMBL2168681 0.71 NPSR1 (0.39) EPHX2CNR2TSHRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
WO-2010050191-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME 興和株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 CTSG 3929/4885CMA1 1278/4885EPHX2 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.